These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 25944732)
21. Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study. Martínez-Castelao A; Cases A; Carballada AT; Iranzo JT; Bronsoms J; Vallès-Prats M; Monserrat DT; Jimenez EM; Nefrologia; 2015; 35(2):179-88. PubMed ID: 26300512 [TBL] [Abstract][Full Text] [Related]
22. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis. Agarwal AK; Silver MR; Reed JE; Dhingra RK; Liu W; Varma N; Stehman-Breen C J Intern Med; 2006 Dec; 260(6):577-85. PubMed ID: 17116009 [TBL] [Abstract][Full Text] [Related]
23. Erythropoiesis-stimulating agent slows the progression of chronic kidney disease: a possibility of a direct action of erythropoietin. Tsuruya K; Yoshida H; Suehiro T; Fujisaki K; Masutani K; Kitazono T Ren Fail; 2016; 38(3):390-6. PubMed ID: 26822074 [TBL] [Abstract][Full Text] [Related]
24. [Effects of dose of erythropoiesis stimulating agents on cardiovascular outcomes, quality of life and costs of haemodialysis. the clinical evaluation of the DOSe of erythropoietins (C.E. DOSE) Trial]. Saglimbene V; D'Alonzo D; Ruospo M; Vecchio M; Natale P; Gargano L; Nicolucci A; Pellegrini F; Craig JC; Triolo G; Procaccini DA; Santoro A; Di Giulio S; La Rosa S; Murgo A; Di Toro Mammarella R; Sambati M; D'Ambrosio N; Greco V; Giannoccaro G; Flammini A; Boccia E; Montalto G; Pagano S; Amarù S; Fici M; Lumaga GB; Mancini E; Veronesi M; Patregnani L; Querques M; Schiavone P; Chimienti S; Palumbo R; Di Franco D; Della Volpe M; Gori E; Salomone M; Iacono A; Moscoloni M; Treglia A; Casu D; Piras AM; Di Silva A; Mandreoli M; Lopez A; Quarello F; Catizone L; Russo G; Forcellini S; Maccarone M; Catucci G; Di Paolo B; Stingone A; D'Angelo B; Guastoni C; Pasquali S; Minoretti C; Bellasi A; Boscutti G; Martone M; David S; Schito F; Urban L; Di Iorio B; Caruso F; Mazzoni A; Musacchio R; Andreoli D; Cossu M; Li Cavoli G; Cornacchiari M; Granata A; Clementi A; Giordano R; Guastoni C; Barzaghi W; Valentini M; Hegbrant J; Tognoni G; Strippoli GF G Ital Nefrol; 2013; 30(2):. PubMed ID: 23832463 [TBL] [Abstract][Full Text] [Related]
25. Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease. Agarwal A; Silver MR; Walczyk M; Liu W; Audhya P J Am Med Dir Assoc; 2007 Feb; 8(2):83-90. PubMed ID: 17289537 [TBL] [Abstract][Full Text] [Related]
26. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial. Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM; Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616 [TBL] [Abstract][Full Text] [Related]
27. Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients. Johansen KL; Finkelstein FO; Revicki DA; Evans C; Wan S; Gitlin M; Agodoa IL Nephrol Dial Transplant; 2012 Jun; 27(6):2418-25. PubMed ID: 22187314 [TBL] [Abstract][Full Text] [Related]
28. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients. Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014 [TBL] [Abstract][Full Text] [Related]
29. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study. Nurko S; Spirko R; Law A; Dennis VW Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200 [TBL] [Abstract][Full Text] [Related]
30. Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Charytan DM; Lewis EF; Desai AS; Weinrauch LA; Ivanovich P; Toto RD; Claggett B; Liu J; Hartley LH; Finn P; Singh AK; Levey AS; Pfeffer MA; McMurray JJ; Solomon SD Am J Kidney Dis; 2015 Sep; 66(3):429-40. PubMed ID: 25935581 [TBL] [Abstract][Full Text] [Related]
31. [Regarding the optimal hemoglobin target range in renal anemia]. Maurin N Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886 [TBL] [Abstract][Full Text] [Related]
32. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R; Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642 [TBL] [Abstract][Full Text] [Related]
33. Initiation of erythropoiesis-stimulating agents and outcomes: a nationwide observational cohort study in anaemic chronic kidney disease patients. Evans M; Carrero JJ; Bellocco R; Barany P; Qureshi AR; Seeberger A; Jacobson SH; Hylander-Rössner B; Rotnitzky A; Sjölander A Nephrol Dial Transplant; 2017 Nov; 32(11):1892-1901. PubMed ID: 27672090 [TBL] [Abstract][Full Text] [Related]
34. Low hemoglobin levels and hypo-responsiveness to erythropoiesis-stimulating agent associated with poor survival in incident Japanese hemodialysis patients. Akizawa T; Saito A; Gejyo F; Suzuki M; Nishizawa Y; Tomino Y; Tsubakihara Y; Akiba T; Hirakata H; Watanabe Y; Kawanishi H; Bessho M; Udagawa Y; Aoki K; Uemura Y; Ohashi Y; Ther Apher Dial; 2014 Oct; 18(5):404-13. PubMed ID: 24571446 [TBL] [Abstract][Full Text] [Related]
35. The effect of maintaining high hemoglobin levels on long-term kidney function in kidney transplant recipients: a randomized controlled trial. Tsujita M; Kosugi T; Goto N; Futamura K; Nishihira M; Okada M; Hiramitsu T; Narumi S; Uchida K; Takeda A; Morozumi K; Maruyama S; Watarai Y Nephrol Dial Transplant; 2019 Aug; 34(8):1409-1416. PubMed ID: 30561729 [TBL] [Abstract][Full Text] [Related]
36. Maintaining control over haemoglobin levels: optimizing the management of anaemia in chronic kidney disease. Bárány P; Müller HJ Nephrol Dial Transplant; 2007 Jun; 22 Suppl 4():iv10-iv18. PubMed ID: 17526545 [TBL] [Abstract][Full Text] [Related]
37. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis]. Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875 [TBL] [Abstract][Full Text] [Related]
38. Thiazolidinediones and Risk of Long-Term Dialysis in Diabetic Patients with Advanced Chronic Kidney Disease: A Nationwide Cohort Study. Chen YH; Chiang MH; Liu JS; Chang YK; Kuo KL; Hung SC; Tai HL; Hsu CC; Tarng DC PLoS One; 2015; 10(6):e0129922. PubMed ID: 26083376 [TBL] [Abstract][Full Text] [Related]
39. A randomized comparison of once weekly epoetin alfa to extended schedule epoetin or darbepoetin in chemotherapy-associated anemia. Steensma DP; Dakhil SR; Novotny PJ; Sloan JA; Johnson DB; Anderson DM; Mattar BI; Moore DF; Nikcevich D; Loprinzi CL Am J Hematol; 2015 Oct; 90(10):877-81. PubMed ID: 26149465 [TBL] [Abstract][Full Text] [Related]
40. An economic evaluation of erythropoiesis-stimulating agents in CKD. Clement FM; Klarenbach S; Tonelli M; Wiebe N; Hemmelgarn B; Manns BJ Am J Kidney Dis; 2010 Dec; 56(6):1050-61. PubMed ID: 20932621 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]